Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$35.00 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)127.28K
Market Cap
HK$1.85B
Enterprise ValueHK$1.20K
Total Cash (Recent Filing)HK$786.48M
Total Debt (Recent Filing)HK$42.72M
Price to Earnings (P/E)18.6
Beta1.50
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.20
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe 2025 inflection to positive operating and net margins alongside materially positive free cash flow indicates the business achieved scalable unit economics and improved cash conversion. This supports durable self-funding of operations, reduces refinancing risk and enables reinvestment for growth if maintained across cycles.
Conservative Balance SheetVery low leverage and a sizable equity base provide financial flexibility to fund R&D, capex and working capital without significant interest burden. This conservative capital structure improves resilience to downturns and preserves optionality for strategic investments or partnerships over the medium term.
Strong Margins & Operating LeverageA high gross margin implies differentiated product economics or pricing power; together with an improving operating margin it shows capacity for operating leverage as revenue scales. That combination supports sustainable cash generation and attractive incremental margins as the business grows.
Bears Say
Profit/Cash Durability RiskRecent profitability and positive FCF are meaningful, but prior-year negative operating and free cash flows show performance volatility. The company must demonstrate repeatable cash generation across cycles; otherwise, episodic profits may not sustain investment plans or cover operating variability long-term.
Historic Losses Pressure EquityA history of material losses means the equity base has borne prior write-downs and may limit margin for error. Continued reinvestment needs or setbacks could pressure returns, force dilution or require external funding, reducing capital allocation flexibility and potentially impairing long-term shareholder value.
Modest Return On EquityAlthough ROE moved into positive territory, a ~7% return on equity is modest relative to the sizable equity base. Sustained shareholder value creation will require higher incremental returns or faster profitable growth; otherwise capital may be deployed inefficiently relative to other opportunities.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$35.00 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$1.85B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Aug 28, 2026 which is in 26 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported HK$0.941 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$0.941 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.091%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
null
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―